Compositions and methods for intranasal delivery of carnosine for treatment of neurodegenerative diseases and disorders
A nasal spray formulation with carnosine, CMC, and CD, designed for stable particle delivery, addresses the blood-brain barrier challenge, offering effective treatment for neurodegenerative diseases with enhanced CNS delivery and reduced side effects.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-03-04
- Publication Date
- 2026-04-30
AI Technical Summary
Developing effective treatments for neurodegenerative diseases and disorders is hindered by the challenge of getting pharmacologic agents across the blood-brain barrier, which limits access to the CNS, and existing delivery methods face issues with stability and unpredictability in intranasal formulations.
A nasal spray composition comprising carnosine, carboxymethylcellulose (CMC), cyclodextrin (CD), and a non-ionic surfactant, formulated to produce stable particles of 10 μm or less in diameter, enhancing intranasal delivery to the CNS.
The composition achieves stable and efficient delivery of carnosine to the CNS, providing therapeutic benefits for neurodegenerative diseases like Parkinson's and Alzheimer's with reduced side effects and improved bioavailability.
Smart Images
Figure IMGF000028_0001 
Figure IMGF000028_0002 
Figure IMGF000029_0001